T cells engineered with CAR specific for HER2 (ClinicalTrials.gov Identifier: NCT01935843) and epidermal growth factor receptor (EGFR, ClinicalTrials.gov Identifier: NCT01869166) are now tested outside of the US, in patients with solid tumors (including ovarian tumors) positive for HER2 and EGFR, respectively. The gene discussed is ERBB2; the disease is ovarian neoplasm.